VERTEX PHARMACEUTICALS INC / MA 4

Director Bruce I. Sachs received an equity compensation grant of 99.941 deferred stock units of Vertex Pharmaceuticals on July 15, 2026.

On July 15, 2026, Vertex Pharmaceuticals director Bruce I. Sachs received an award of 99.941 deferred stock units, each representing one share of common stock, valued at approximately $475 based on the reported unit value of about $4.76 per unit, as part of his board compensation. These deferred stock units will be settled in common stock upon the earliest of his termination from the board, a change in control of the company, or his disability or death. Following this grant, Sachs beneficially owns 15,771.807 shares of Vertex common stock (including the deferred units), representing a relatively small, routine increase in his equity exposure to the company.

Filing Facts

CIK

875320

Ticker

VRTX

Form

4

Source Type

fda

Accession

0000875320-26-000249

Alert Tier

4